|
1
|
Rolain JM, Colson P and Raoult D:
Recycling of chloroquine and its hydroxyl analogue to face
bacterial, fungal and viral infections in the 21st century. Int J
Antimicrob Agents. 30:297–308. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ruiz-Irastorza G, Ramos-Casals M,
Brito-Zeron P and Khamashta MA: Clinical efficacy and side effects
of antimalarials in systemic lupus erythematosus: A systematic
review. Ann Rheum Dis. 69:20–28. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Khraishi MM and Singh G: The role of
anti-malarials in rheumatoid arthritis-the American experience.
Lupus. 5 (Suppl 1):S41–S44. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Demarchi J, Papasidero S, Medina MA, Klajn
D, Moral RC, Rillo O, Martiré V, Crespo G, Secco A, Pellet AC, et
al: Primary Sjögren's syndrome: Extraglandular manifestations and
hydroxychloroquine therapy. Clin Rheumatol. 36:2455–2460. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tektonidou MG, Andreoli L, Limper M,
Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T,
Ferrer-Oliveras R, Hambly K, et al: EULAR recommendations for the
management of antiphospholipid syndrome in adults. Ann Rheum Dis.
78:1296–1304. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kerrigan SA and McInnes IB: Reflections on
‘older’ drugs: Learning new lessons in rheumatology. Nat Rev
Rheumatol. 16:179–183. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schrezenmeier E and Dörner T: Mechanisms
of action of hydroxychloroquine and chloroquine: Implications for
rheumatology. Nat Rev Rheumatol. 16:155–166. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nirk EL, Reggiori F and Mauthe M:
Hydroxychloroquine in rheumatic autoimmune disorders and beyond.
EMBO Mol Med. 12:e124762020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McInnes IB and Schett G: Cytokines in the
pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 7:429–442.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wirestam L, Arve S, Linge P and Bengtsson
AA: Neutrophils-important communicators in systemic lupus
erythematosus and antiphospholipid syndrome. Front Immunol.
10:27342019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fanouriakis A, Kostopoulou M, Andersen J,
Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria
A, et al: EULAR recommendations for the management of systemic
lupus erythematosus: 2023 update. Ann Rheum Dis. 83:15–29. 2023.
View Article : Google Scholar
|
|
12
|
Abd Rahman R, Tun KM, Atan IK, Said MS,
Mustafar R and Zainuddin AA: New benefits of hydroxychloroquine in
pregnant women with systemic lupus erythematosus: A retrospective
study in a tertiary centre. Rev Bras Ginecol Obstet. 42:705–711.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kerschbaumer A, Sepriano A, Smolen JS, van
der Heijde D, Dougados M, van Vollenhoven R, McInnes IB, Bijlsma
JWJ, Burmester GR, de Wit M, et al: Efficacy of pharmacological
treatment in rheumatoid arthritis: A systematic literature research
informing the 2019 update of the EULAR recommendations for
management of rheumatoid arthritis. Ann Rheum Dis. 79:744–759.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ramos-Casals M, Brito-Zerón P, Bombardieri
S, Bootsma H, De Vita S, Dörner T, Fisher BA, Gottenberg JE,
Hernandez-Molina G, Kocher A, et al: EULAR recommendations for the
management of Sjögren's syndrome with topical and systemic
therapies. Ann Rheum Dis. 79:3–18. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wolstencroft PW, Casciola-Rosen L and
Fiorentino DF: Association between autoantibody phenotype and
cutaneous adverse reactions to hydroxychloroquine in
dermatomyositis. JAMA Dermatol. 154:1199–1203. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rees F, Doherty M, Grainge MJ, Lanyon P
and Zhang W: The worldwide incidence and prevalence of systemic
lupus erythematosus: A systematic review of epidemiological
studies. Rheumatology (Oxford). 56:1945–1961. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jung H, Bobba R, Su J, Shariati-Sarabi Z,
Gladman DD, Urowitz M, Lou W and Fortin PR: The protective effect
of antimalarial drugs on thrombovascular events in systemic lupus
erythematosus. Arthritis Rheum. 62:863–868. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hsu CY, Lin YS, Su YJ, Lin HF, Lin MS, Syu
YJ, Cheng TT, Yu SF, Chen JF and Chen TH: Effect of long-term
hydroxychloroquine on vascular events in patients with systemic
lupus erythematosus: A database prospective cohort study.
Rheumatology (Oxford). 56:2212–2221. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsakonas E, Joseph L, Esdaile JM,
Choquette D, Senécal JL, Cividino A, Danoff D, Osterland CK, Yeadon
C and Smith CD: A long-term study of hydroxychloroquine withdrawal
on exacerbations in systemic lupus erythematosus. Lupus. 7:80–85.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aouhab Z, Hong H, Felicelli C, Tarplin S
and Ostrowski RA: Outcomes of systemic lupus erythematosus in
patients who discontinue hydroxychloroquine. ACR Open Rheumatol.
1:593–599. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Costedoat-Chalumeau N, Dunogué B, Morel N,
Le Guern V and Guettrot-Imbert G: Hydroxychloroquine: A
multifaceted treatment in lupus. Presse Med. 43((6 Pt 2)):
e167–e180. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tunks RD, Clowse ME, Miller SG, Brancazio
LR and Barker PC: Maternal autoantibody levels in congenital heart
block and potential prophylaxis with antiinflammatory agents. Am J
Obstet Gynecol. 208:64.e1–7. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen FY, Chen SW, Chen X, Huang JY, Ye Z
and Wei JC: Hydroxychloroquine might reduce risk of incident
endometriosis in patients with systemic lupus erythematosus: A
retrospective population-based cohort study. Lupus. 30:1609–1616.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang DH, Leong PY, Sia SK, Wang YH and Wei
JC: Long-Term hydroxychloroquine therapy and risk of coronary
artery disease in patients with systemic lupus erythematosus. J
Clin Med. 8:7962019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu KQ, Zhu ZZ, Wei SR, Zeng HS and Mo HY:
Systemic lupus erythematosus complicated with cardiovascular
disease. Int J Rheum Dis. 26:1429–1431. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lo CH, Wei JC, Wang YH, Tsai CF, Chan KC,
Li LC, Lo TH and Su CH: Hydroxychloroquine does not increase the
risk of cardiac arrhythmia in common rheumatic diseases: A
nationwide population-based cohort study. Front Immunol.
12:6318692021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lo CH, Wang YH, Tsai CF, Chan KC, Li LC,
Lo TH, Wei JC and Su CH: Association of hydroxychloroquine and
cardiac arrhythmia in patients with systemic lupus erythematosus: A
population-based case control study. PLoS One. 16:e02519182021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu CY, Tan M, Huang JY, Chiou JY and Wei
JC: Hydroxychloroquine is neutral in risk of chronic kidney disease
in patients with systemsic lupus erythematosus. Ann Rheum Dis.
81:e752022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shinjo SK, Bonfá E, Wojdyla D, Borba EF,
Ramirez LA, Scherbarth HR, Brenol JC, Chacón-Diaz R, Neira OJ,
Berbotto GA, et al: Antimalarial treatment may have a
time-dependent effect on lupus survival: Data from a multinational
Latin American inception cohort. Arthritis Rheum. 62:855–862. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kariburyo F, Xie L, Sah J, Li N and
Lofland JH: Real-world medication use and economic outcomes in
incident systemic lupus erythematosus patients in the United
States. J Med Econ. 23:1–9. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y
and Kawahata K: Hydroxychloroquine improves the disease activity
and allows the reduction of the corticosteroid dose regardless of
background treatment in japanese patients with systemic lupus
erythematosus. Intern Med. 58:1257–1262. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cervera R, Piette JC, Font J, Khamashta
MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A,
Kontopoulou-Griva I, et al: Antiphospholipid syndrome: Clinical and
immunologic manifestations and patterns of disease expression in a
cohort of 1,000 patients. Arthritis Rheum. 46:1019–1027. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Petri M: Antiphospholipid syndrome. Transl
Res. 225:70–81. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Miranda S, Billoir P, Damian L, Thiebaut
PA, Schapman D, Le Besnerais M, Jouen F, Galas L, Levesque H, Le
Cam-Duchez V, et al: Hydroxychloroquine reverses the prothrombotic
state in a mouse model of antiphospholipid syndrome: Role of
reduced inflammation and endothelial dysfunction. PLoS One.
14:e02126142019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sayar Z, Moll R, Isenberg D and Cohen H:
Thrombotic antiphospholipid syndrome: A practical guide to
diagnosis and management. Thromb Res. 198:213–221. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schreiber K, Breen K, Parmar K, Rand JH,
Wu XX and Hunt BJ: The effect of hydroxychloroquine on haemostasis,
complement, inflammation and angiogenesis in patients with
antiphospholipid antibodies. Rheumatology (Oxford). 57:120–124.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Müller-Calleja N, Ritter S, Hollerbach A,
Falter T, Lackner KJ and Ruf W: Complement C5 but not C3 is
expendable for tissue factor activation by cofactor-independent
antiphospholipid antibodies. Blood Adv. 2:979–986. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guo Y, Gao F, Wang X, Pan Z, Wang Q, Xu S,
Pan S, Li L, Zhao D and Qian J: Spontaneous formation of neutrophil
extracellular traps is associated with autophagy. Sci Rep.
11:240052021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Boone BA, Murthy P, Miller-Ocuin J,
Doerfler WR, Ellis JT, Liang X, Ross MA, Wallace CT, Sperry JL,
Lotze MT, et al: Chloroquine reduces hypercoagulability in
pancreatic cancer through inhibition of neutrophil extracellular
traps. BMC Cancer. 18:6782018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen Y, Xu W, Huang S, Li J, Li T, Chen J,
Lu Y and Zhang J: Analysis of pregnancy outcomes in patients
exhibiting recurrent miscarriage with concurrent low-titer
antiphospholipid antibodies. Am J Reprod Immunol. 92:e139402024.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sciascia S, Hunt BJ, Talavera-Garcia E,
Lliso G, Khamashta MA and Cuadrado MJ: The impact of
hydroxychloroquine treatment on pregnancy outcome in women with
antiphospholipid antibodies. Am J Obstet Gynecol.
214:273.e1–273.e8. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schreiber K, Breen K, Cohen H, Jacobsen S,
Middeldorp S, Pavord S, Regan L, Roccatello D, Robinson SE,
Sciascia S, et al: HYdroxychloroquine to improve pregnancy outcome
in women with AnTIphospholipid antibodies (HYPATIA. Protocol: A
multinational randomized controlled trial of hydroxychloroquine
versus placebo in addition to standard treatment in pregnant women
with antiphospholipid syndrome or antibodies. Semin Thromb Hemost.
43:562–571. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mar N, Kosowicz R and Hook K: Recurrent
thrombosis prevention with intravenous immunoglobulin and
hydroxychloroquine during pregnancy in a patient with history of
catastrophic antiphospholipid syndrome and pregnancy loss. J Thromb
Thrombolysis. 38:196–200. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Smolen JS, Aletaha D and McInnes IB:
Rheumatoid arthritis. Lancet. 388:2023–2038. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schapink L, van den Ende CHM, Gevers LAHA,
van Ede AE and den Broeder AA: The effects of methotrexate and
hydroxychloroquine combination therapy vs methotrexate monotherapy
in early rheumatoid arthritis patients. Rheumatology (Oxford).
58:131–134. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sharma TS, Wasko MC, Tang X, Vedamurthy D,
Yan X, Cote J and Bili A: Hydroxychloroquine use is associated with
decreased incident cardiovascular events in rheumatoid arthritis
patients. J Am Heart Assoc. 5:e0028672016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wu CL, Chang CC, Kor CT, Yang TH, Chiu PF,
Tarng DC and Hsu CC: Hydroxychloroquine use and risk of CKD in
patients with rheumatoid arthritis. Clin J Am Soc Nephrol.
13:702–709. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hazlewood GS, Barnabe C, Tomlinson G,
Marshall D, Devoe DJ and Bombardier C: Methotrexate monotherapy and
methotrexate combination therapy with traditional and biologic
disease modifying anti-rheumatic drugs for rheumatoid arthritis: A
network meta-analysis. Cochrane Database Syst Rev.
2016:CD0102272016.PubMed/NCBI
|
|
49
|
Zhang L, Chen F, Geng S, Wang X, Gu L,
Lang Y, Li T and Ye S: Methotrexate (MTX) plus hydroxychloroquine
versus MTX plus leflunomide in patients with MTX-resistant active
rheumatoid arthritis: A 2-year cohort study in real world. J
Inflamm Res. 13:1141–1150. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia
V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS,
et al: Therapies for active rheumatoid arthritis after methotrexate
failure. N Engl J Med. 369:307–318. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shi ZC, Fei HP and Wang ZL:
Cost-effectiveness analysis of etanercept plus methotrexate vs
triple therapy in treating Chinese rheumatoid arthritis patients.
Medicine (Baltimore). 99:e166352020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Østergaard M, van Vollenhoven RF, Rudin A,
Hetland ML, Heiberg MS, Nordström DC, Nurmohamed MT, Gudbjornsson
B, Ørnbjerg LM, Bøyesen P, et al: Certolizumab pegol, abatacept,
tocilizumab or active conventional treatment in early rheumatoid
arthritis: 48-week clinical and radiographic results of the
investigator-initiated randomised controlled NORD-STAR trial. Ann
Rheum Dis. 82:1286–1295. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Haridoss M, Sasidharan A, Kumar S,
Rajsekar K, Venkataraman K and Bagepally BS: Cost-Utility analysis
of TNF-α inhibitors, B cell inhibitors and JAK inhibitors versus
csDMARDs for rheumatoid arthritis treatment. Appl Health Econ
Health Policy. 22:885–896. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Combe B, Kivitz A, Tanaka Y, van der
Heijde D, Simon JA, Baraf HSB, Kumar U, Matzkies F, Bartok B, Ye L,
et al: Filgotinib versus placebo or adalimumab in patients with
rheumatoid arthritis and inadequate response to methotrexate: A
phase III randomised clinical trial. Ann Rheum Dis. 80:848–858.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bredemeier M, Duarte ÂL, Pinheiro MM,
Kahlow BS, Macieira JC, Ranza R, Miranda JR, Valim V, de Castro GR,
Bértolo MB, et al: The effect of antimalarials on the safety and
persistence of treatment with biologic agents or Janus kinase
inhibitors in rheumatoid arthritis. Rheumatology (Oxford).
63:456–465. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Qin B, Wang J, Yang Z, Yang M, Ma N, Huang
F and Zhong R: Epidemiology of primary Sjögren's syndrome: A
systematic review and meta-analysis. Ann Rheum Dis. 74:1983–1989.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Meijer JM, Meiners PM, Slater JJ,
Spijkervet FK, Kallenberg CG, Vissink A and Bootsma H:
Health-related quality of life, employment and disability in
patients with Sjogren's syndrome. Rheumatology (Oxford).
489:1077–1082. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yavuz S, Asfuroğlu E, Bicakcigil M and
Toker E: Hydroxychloroquine improves dry eye symptoms of patients
with primary Sjogren's syndrome. Rheumatol Int. 31:1045–1049. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hernández-Molina G, Valim V, Secco A,
Atisha-Fregoso Y, Guerra E, Adrover M, Santos AJ and Catalán-Pellet
A: Do antimalarials protect against damage accrual in primary
Sjögren's syndrome? Results from a Latin-American retrospective
cohort. Clin Exp Rheumatol. 36 (Suppl 112):S182–S185. 2018.
|
|
60
|
Yoon CH, Lee HJ, Lee EY, Lee EB, Lee WW,
Kim MK and Wee WR: Effect of hydroxychloroquine treatment on dry
eyes in subjects with primary Sjögren's Syndrome: A double-blind
randomized control study. J Korean Med Sci. 31:1127–1135. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wang SQ, Zhang LW, Wei P and Hua H: Is
hydroxychloroquine effective in treating primary Sjogren's
syndrome: A systematic review and meta-analysis. BMC Musculoskelet
Disord. 18:1862017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wang X, Zhang T, Guo Z, Pu J, Riaz F, Feng
R, Fang X, Song J, Liang Y, Wu Z, et al: The efficiency of
hydroxychloroquine for the treatment of primary Sjögren's syndrome:
A systematic review and meta-analysis. Front Pharmacol.
12:6937962021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sontheimer RD: Aminoquinoline antimalarial
therapy in dermatomyositis-are we missing opportunities with
respect to comorbidities and modulation of extracutaneous disease
activity? Ann Transl Med. 6:1542018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Olson NY and Lindsley CB: Adjunctive use
of hydroxychloroquine in childhood dermatomyositis. J Rheumatol.
16:1545–1547. 1989.PubMed/NCBI
|
|
65
|
Bloom BJ, Tucker LB, Klein-Gitelman M,
Miller LC and Schaller JG: Worsening of the rash of juvenile
dermatomyositis with hydroxychloroquine therapy. J Rheumatol.
21:2171–2172. 1994.PubMed/NCBI
|
|
66
|
Jokar M, Mirfeizi Z and Keyvanpajouh K:
The effect of hydroxychloroquine on symptoms of knee
osteoarthritis: A double-blind randomized controlled clinical
trial. Iran J Med Sci. 38:221–226. 2013.PubMed/NCBI
|
|
67
|
Singh A, Kotlo A, Wang Z, Dissanayaka T,
Das S and Antony B: Efficacy and safety of hydroxychloroquine in
osteoarthritis: A systematic review and meta-analysis of randomized
controlled trials. Korean J Intern Med. 37:210–221. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Woźniacka A: Antimalarials-old drugs are
new again. Postepy Dermatol Alergol. 39:239–244. 2022.PubMed/NCBI
|
|
69
|
Martín-Iglesias D, Artaraz J, Fonollosa A,
Ugarte A, Arteagabeitia A and Ruiz-Irastorza G: Evolution of
retinal changes measured by optical coherence tomography in the
assessment of hydroxychloroquine ocular safety in patients with
systemic lupus erythematosus. Lupus. 28:555–559. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Mukwikwi ER, Pineau CA, Vinet E, Clarke
AE, Nashi E, Kalache F, Grenier LP and Bernatsky S: Retinal
Complications in patients with systemic lupus erythematosus treated
with antimalarial drugs. J Rheumatol. 47:553–556. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Cramarossa G, Liu HY, Turk MA and Pope JE:
Guidelines on prescribing and monitoring antimalarials in rheumatic
diseases: A systematic review. Clin Exp Rheumatol. 39:407–412.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Angelakis E, Million M, Kankoe S, Lagier
JC, Armougom F, Giorgi R and Raoult D: Abnormal weight gain and gut
microbiota modifications are side effects of long-term doxycycline
and hydroxychloroquine treatment. Antimicrob Agents Chemother.
58:3342–3347. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ponticelli C and Moroni G:
Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert
Opin Drug Saf. 16:411–419. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cairoli E, Danese N, Teliz M, Bruzzone MJ,
Ferreira J, Rebella M and Cayota A: Cumulative dose of
hydroxychloroquine is associated with a decrease of resting heart
rate in patients with systemic lupus erythematosus: A pilot study.
Lupus. 24:1204–1209. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Tselios K, Gladman DD, Harvey P, Akhtari
S, Su J and Urowitz MB: Abnormal cardiac biomarkers in patients
with systemic lupus erythematosus and no prior heart disease: A
consequence of antimalarials? J Rheumatol. 46:64–69. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Sorour AA, Kurmann RD, Shahin YE, Crowson
CS, Achenbach SJ, Mankad R and Myasoedova E: Use of
hydroxychloroquine and risk of heart failure in patients with
rheumatoid arthritis. J Rheumatol. 48:1508–1511. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Chatre C, Roubille F, Vernhet H, Jorgensen
C and Pers YM: Cardiac complications attributed to chloroquine and
hydroxychloroquine: A systematic review of the literature. Drug
Saf. 41:919–931. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Quiñones ME, Joseph JK, Dowell S, Moore
HJ, Karasik PE, Fonarow GC, Fletcher RD, Cheng Y, Zeng-Treitler Q,
Arundel C, et al: Hydroxychloroquine and risk of long QT syndrome
in rheumatoid arthritis: A veterans cohort study with nineteen-year
follow-up. Arthritis Care Res (Hoboken). 75:1571–1579. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Tehrani R, Ostrowski RA, Hariman R and Jay
WM: Ocular toxicity of hydroxychloroquine. Semin Ophthalmol.
23:201–209. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Yusuf IH, Sharma S, Luqmani R and Downes
SM: Hydroxychloroquine retinopathy. Eye (Lond). 31:828–845. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Browning DJ and Lee C: Somatotype, the
risk of hydroxychloroquine retinopathy and safe daily dosing
guidelines. Clin Ophthalmol. 12:811–818. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Browning DJ and Lee C: Scotoma analysis of
10-2 visual field testing with a white target in screening for
hydroxychloroquine retinopathy. Clin Ophthalmol. 9:943–952. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Modi YS and Singh RP: Bull's-eye
maculopathy associated with hydroxychloroquine. N Engl J Med.
380:16562019. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Marmor MF, Kellner U, Lai TY, Melles RB
and Mieler WF; American Academy of Ophthalmology, : Recommendations
on screening for chloroquine and hydroxychloroquine retinopathy
(2016 Revision). Ophthalmology. 123:1386–1394. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wolfe F and Marmor MF: Rates and
predictors of hydroxychloroquine retinal toxicity in patients with
rheumatoid arthritis and systemic lupus erythematosus. Arthritis
Care Res (Hoboken). 62:775–784. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Spinelli FR, Moscarelli E, Ceccarelli F,
Miranda F, Perricone C, Truglia S, Garufi C, Massaro L, Morello F,
Alessandri C, et al: Treating lupus patients with antimalarials:
Analysis of safety profile in a single-center cohort. Lupus.
27:1616–1623. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Kellner S, Weinitz S, Farmand G and
Kellner U: Cystoid macular oedema and epiretinal membrane formation
during progression of chloroquine retinopathy after drug cessation.
Br J Ophthalmol. 98:200–206. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Muller R: Systemic toxicity of chloroquine
and hydroxychloroquine: Prevalence, mechanisms, risk factors,
prognostic and screening possibilities. Rheumatol Int.
41:1189–1202. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Lipner SR and Wang Y: Retrospective
analysis of dermatologic adverse events associated with
hydroxychloroquine reported to the US food and drug administration.
J Am Acad Dermatol. 83:1527–1529. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Coulombe J and Boccara O:
Hydroxychloroquine-related skin discoloration. CMAJ. 189:E2122017.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Dos Reis Neto ET, Kakehasi AM, de Medeiros
Pinheiro M, Ferreira GA, Marques CDL, da Mota LMH, Dos Santos Paiva
E, Pileggi GCS, Sato EI, Reis APMG, et al: Revisiting
hydroxychloroquine and chloroquine for patients with chronic
immunity-mediated inflammatory rheumatic diseases. Adv Rheumatol.
60:322020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Léger JM, Puifoulloux H, Dancea S, Hauw
JJ, Bouche P, Rougemont D and Laplane D: Chloroquine
neuromyopathies: 4 cases during antimalarial prevention. Rev Neurol
(Paris). 142:746–752. 1986.(In French). PubMed/NCBI
|
|
93
|
Pagès M and Pagès AM: Peripheral nerve
lesions in chloroquine-induced neuromyopathies. Ann Pathol.
4:289–295. 1984.(In French). PubMed/NCBI
|
|
94
|
Doyno C, Sobieraj DM and Baker WL:
Toxicity of chloroquine and hydroxychloroquine following
therapeutic use or overdose. Clin Toxicol (Phila). 59:12–23. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Casado E, Gratacós J, Tolosa C, Martínez
JM, Ojanguren I, Ariza A, Real J, Sanjuán A and Larrosa M:
Antimalarial myopathy: An underdiagnosed complication? Prospective
longitudinal study of 119 patients. Ann Rheum Dis. 65:385–390.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Abdel-Hamid H, Oddis CV and Lacomis D:
Severe hydroxychloroquine myopathy. Muscle Nerve. 38:1206–1210.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Jafri K, Zahed H, Wysham KD, Patterson S,
Nolan AL, Bucknor MD and Chaganti RK: Antimalarial myopathy in a
systemic lupus erythematosus patient with quadriparesis and
seizures: A case-based review. Clin Rheumatol. 36:1437–1444. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Chary MA, Barbuto AF, Izadmehr S, Hayes BD
and Burns MM: COVID-19: Therapeutics and their toxicities. J Med
Toxicol. 16:284–294. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Gasmi A, Peana M, Noor S, Lysiuk R, Menzel
A, Benahmed AG and Bjørklund G: Chloroquine and hydroxychloroquine
in the treatment of COVID-19: The never-ending story. Appl
Microbiol Biotechnol. 105:1333–1343. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H,
Li Y, Hu Z, Zhong W and Wang M: Hydroxychloroquine, a less toxic
derivative of chloroquine, is effective in inhibiting SARS-CoV-2
infection in vitro. Cell Discov. 6:162020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Martinez GP, Zabaleta ME, Di Giulio C,
Charris JE and Mijares MR: The role of chloroquine and
hydroxychloroquine in immune regulation and diseases. Curr Pharm
Des. 26:4467–4485. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Ye Q, Wang B and Mao J: The pathogenesis
and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect.
80:607–613. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Bajpai J, Pradhan A, Singh A and Kant S:
Hydroxychloroquine and COVID-19-A narrative review. Indian J
Tuberc. 67((4S)): S147–S154. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Gautret P, Lagier JC, Parola P, Hoang VT,
Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE,
et al: Hydroxychloroquine and azithromycin as a treatment of
COVID-19: Results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 56:1059492020. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Gautret P, Lagier JC, Parola P, Hoang VT,
Meddeb L, Sevestre J, Mailhe M, Doudier B, Aubry C, Amrane S, et
al: Clinical and microbiological effect of a combination of
hydroxychloroquine and azithromycin in 80 COVID-19 patients with at
least a six-day follow up: A pilot observational study. Travel Med
Infect Dis. 34:1016632020. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Sarhan RM, Harb HS, Warda AE, Salem-Bekhit
MM, Shakeel F, Alzahrani SA, Madney YM and Boshra MS: Efficacy of
the early treatment with tocilizumab-hydroxychloroquine and
tocilizumab-remdesivir in severe COVID-19 patients. J Infect Public
Health. 15:116–122. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Réa-Neto Á, Bernardelli RS, Câmara BMD,
Reese FB, Queiroga MVO and Oliveira MC: An open-label randomized
controlled trial evaluating the efficacy of
chloroquine/hydroxychloroquine in severe COVID-19 patients. Sci
Rep. 11:90232021. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Cavalcanti AB, Zampieri FG, Rosa RG,
Azevedo LCP, Veiga VC, Avezum A, Damiani LP, Marcadenti A,
Kawano-Dourado L, Lisboa T, et al: Hydroxychloroquine with or
without azithromycin in mild-to-moderate Covid-19. N Engl J Med.
383:2041–2052. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Ibáñez S, Martínez O, Valenzuela F, Silva
F and Valenzuela O: Hydroxychloroquine and chloroquine in COVID-19:
Should they be used as standard therapy? Clin Rheumatol.
39:2461–2465. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zang Y, Han X, He M, Shi J and Li Y:
Hydroxychloroquine use and progression or prognosis of COVID-19: A
systematic review and meta-analysis. Naunyn Schmiedebergs Arch
Pharmacol. 394:775–782. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Hernandez AV, Roman YM, Pasupuleti V,
Barboza JJ and White CM: Hydroxychloroquine or chloroquine for
treatment or prophylaxis of COVID-19: A living systematic review.
Ann Intern Med. 173:287–296. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Singh H, Chauhan P and Kakkar AK:
Hydroxychloroquine for the treatment and prophylaxis of COVID-19:
The journey so far and the road ahead. Eur J Pharmacol.
890:1737172021. View Article : Google Scholar : PubMed/NCBI
|
